Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination.

• Main Authors: Jasmin Nessler, Karelle Bénardais, Viktoria Gudi, Andrea Hoffmann, Laura Salinas Tejedor, Stefanie Janßen, Chittappen Kandiyil Prajeeth, Wolfgang Baumgärtner, Annemieke Kavelaars, Cobi J Heijnen, Cindy van Velthoven, Florian Hansmann, Thomas Skripuletz, Martin Stangel
• Format: Article
• Language: English
• Published: Public Library of Science (PLoS) 2013-01-01
• Series: PLoS ONE
• Online Access: http://europepmc.org/articles/PMC3724887?pdf=render

For the treatment of patients with multiple sclerosis there are no regenerative approaches to enhance remyelination. Mesenchymal stem cells (MSC) have been proposed to exert such regenerative functions. Intravenous administration of human MSC reduced the clinical severity of experimental autoimmune encephalomyelitis (EAE), an animal model mimicking some aspects of multiple sclerosis. However, it is not clear if this effect was achieved by systemic immunomodulation or if there is an active neuroregeneration in the central nervous system (CNS). In order to investigate remyelination and regeneration in the CNS we analysed the effects of intravenously and intranasally applied murine and human bone marrow-derived MSC on cuprizone induced demyelination, a toxic animal model which allows analysis of remyelination without the influence of the peripheral immune system. In contrast to EAE no effects of MSC on de- and remyelination and glial cell reactions were found. In addition, neither murine nor human MSC entered the lesions in the CNS in this toxic model. In conclusion, MSC are not directed into CNS lesions in the cuprizone model where the blood-brain-barrier is intact and thus cannot provide support for regenerative processes.